MX2009006446A - Derivados de espiro-piperidina. - Google Patents

Derivados de espiro-piperidina.

Info

Publication number
MX2009006446A
MX2009006446A MX2009006446A MX2009006446A MX2009006446A MX 2009006446 A MX2009006446 A MX 2009006446A MX 2009006446 A MX2009006446 A MX 2009006446A MX 2009006446 A MX2009006446 A MX 2009006446A MX 2009006446 A MX2009006446 A MX 2009006446A
Authority
MX
Mexico
Prior art keywords
sup
piperidine derivatives
spiro
present
concerned
Prior art date
Application number
MX2009006446A
Other languages
English (en)
Inventor
Raffaello Masciadri
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009006446A publication Critical patent/MX2009006446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos derivados de espiro-piperidina como antagonistas del receptor de V1a, a su obtención, a composiciones farmacéuticas que los contienen y a su utilización como medicamentos. Los compuestos activos de la presente invención son útiles para la prevención y/o el tratamiento de la ansiedad, de trastornos depresivos y de otras enfermedades. En particular, la presente invención se refiere a compuestos de la fórmula general (I) (ver fórmula I) en donde R1 a R5, R5, X, Y y A tienen los significados definidos en la descripción.
MX2009006446A 2006-12-22 2007-12-13 Derivados de espiro-piperidina. MX2009006446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127078 2006-12-22
PCT/EP2007/063882 WO2008077811A1 (en) 2006-12-22 2007-12-13 Spiro-piperidine derivatives

Publications (1)

Publication Number Publication Date
MX2009006446A true MX2009006446A (es) 2009-06-26

Family

ID=39301516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006446A MX2009006446A (es) 2006-12-22 2007-12-13 Derivados de espiro-piperidina.

Country Status (18)

Country Link
US (3) US7495008B2 (es)
EP (1) EP2125726B1 (es)
JP (1) JP2010513385A (es)
KR (1) KR101122969B1 (es)
CN (1) CN101563323B (es)
AR (1) AR064480A1 (es)
AT (1) ATE517866T1 (es)
AU (1) AU2007338116B2 (es)
BR (1) BRPI0720845A2 (es)
CA (1) CA2674518A1 (es)
CL (1) CL2007003719A1 (es)
ES (1) ES2370047T3 (es)
MX (1) MX2009006446A (es)
NO (1) NO20092264L (es)
PE (1) PE20081486A1 (es)
RU (1) RU2009123134A (es)
TW (1) TWI339663B (es)
WO (1) WO2008077811A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101122969B1 (ko) * 2006-12-22 2012-03-22 에프. 호프만-라 로슈 아게 스피로-피페리딘 유도체
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
PT2670752E (pt) * 2011-02-02 2016-06-14 Vertex Pharma Piperidinamidas pirrolopirazina-espirocíclicas como moduladores de canais iónicos
LT3083633T (lt) * 2013-12-19 2018-02-12 F. Hoffmann-La Roche Ag Spiro-oksazolonai
CN104557777B (zh) * 2015-01-09 2016-08-31 万华化学集团股份有限公司 一种n-甲基哌嗪的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037287A1 (en) * 1990-03-02 1991-09-03 Ben E. Evans Spirocyclic oxytocin antagonists
WO1994007496A1 (en) * 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
BR0116113A (pt) 2000-12-12 2004-08-03 Neurogen Corp Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
BR0214455A (pt) 2001-11-27 2004-11-03 Hoffmann La Roche Derivados benzotiazol
WO2005063754A1 (en) * 2003-12-22 2005-07-14 Pfizer Limited Triazole derivatives as vasopressin antagonists
KR101122969B1 (ko) * 2006-12-22 2012-03-22 에프. 호프만-라 로슈 아게 스피로-피페리딘 유도체

Also Published As

Publication number Publication date
TWI339663B (en) 2011-04-01
US7678806B2 (en) 2010-03-16
US7495008B2 (en) 2009-02-24
CN101563323B (zh) 2012-07-04
US20080161304A1 (en) 2008-07-03
TW200833696A (en) 2008-08-16
KR20090082505A (ko) 2009-07-30
ATE517866T1 (de) 2011-08-15
AU2007338116B2 (en) 2012-04-26
NO20092264L (no) 2009-06-24
KR101122969B1 (ko) 2012-03-22
JP2010513385A (ja) 2010-04-30
US20080280898A1 (en) 2008-11-13
RU2009123134A (ru) 2011-01-27
AU2007338116A1 (en) 2008-07-03
US20080167333A1 (en) 2008-07-10
CA2674518A1 (en) 2008-07-03
EP2125726A1 (en) 2009-12-02
PE20081486A1 (es) 2008-10-18
CN101563323A (zh) 2009-10-21
BRPI0720845A2 (pt) 2014-03-04
EP2125726B1 (en) 2011-07-27
US7501432B2 (en) 2009-03-10
CL2007003719A1 (es) 2008-07-11
ES2370047T3 (es) 2011-12-12
AR064480A1 (es) 2009-04-01
WO2008077811A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2008080844A9 (en) Azaspiro derivatives
MX2009005507A (es) Derivados de espiro-piperidina.
MX2009007411A (es) Derivados de espiropiperidina-glicinamida.
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
GB0625648D0 (en) Compounds
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
WO2003064404A1 (fr) Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
MX2009006454A (es) Derivados de espiro-piperidina.
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
MX2009005544A (es) Indoles.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2009014001A (es) Derivados de isoxazol-imidazol.
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.

Legal Events

Date Code Title Description
FG Grant or registration